Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 8, 2013, Pages

  Chen, Yizhi ^a   Gong, Zhixiang ^b   Chen, Xiangmei ^a   Tang, Li ^a   Zhao, Xuezhi ^c   Yuan, Qing ^d   Cai, Guangyan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Chinese PLA 532 Hospital   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d 309TH HOSPITAL OF PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; CYCLOPHOSPHAMIDE; PREDNISONE; PROTEIN; TRIPTERYGIUM WILFORDII EXTRACT; HERBACEOUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ALBUMIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CHINESE MEDICINE; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; LEUKOPENIA; META ANALYSIS; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN URINE LEVEL; REMISSION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; METHODOLOGY; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIPTERYGIUM; PROCEDURES;

CYCLOPHOSPHAMIDE; DRUGS, CHINESE HERBAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEPHROTIC SYNDROME; PHYTOTHERAPY; PREDNISONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TRIPTERYGIUM;

EID: 84893382394     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008568.pub2     Document Type: Review

References (85)

1. A-Da LT, Su JH, Wang ZC. Clinical random control observation of 18 cases of patients with primary IgA nephropathy syndrome treated with tripterygium glycosides tablet. Dangdai Yixue [China Contemporary Medicine] 2008;15(10):12-3.
2. Chen ZM, Chen ZJ. Clinical analysis of 36 cases of refractory nephrotic syndrome treated by high-dosage Tripterygium glycosides. Zhongguo Quanke Yixue [Chinese General Practice] 2003;6(11):948.
3. Han JH, Mou ZL, Wang JP. Combination of Tripterygium glycosides and cyclosporin A for the treatment of refractory nephrotic syndrome. Linchuang Huicui [Clinical Focus] 1999;14(18):841-2.
4. Li Z, Zhang YF, Liu F. Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Hainan Yixue [Hainan Medical Journal] 1999;10(6):191-2.
5. Li Z, Zhang YF, Liu F. Clinical observation of 48 cases of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii and quadruple chemotherapy. Yi Xue Wen Xuan [Anthology of Medicine] 2000;19(2):139-40.
6. Song HX, Wang ZT, Chen XT. Clinical study of combined treatment of cyclophosphamide and Tripterygium wilfordii for nephrotic syndrome. Lin Yi Yi Zhuan Xue Bao [Journal of Linyi Medical College] 1998;20(2):109-12.
7. Wen YQ, Zhu QL, Wang MC, Ren ZQ, Liu ML, Hu GL. Clinical therapeutic analysis of primary nephrotic syndrome treated by prednisone and Tripterygium wilfordii. Zhonghua Shenzangbing Zazhi [Chinese Journal of Nephrology] 1993;9(3):190.
8. Yuan DS, Wang YR. Clinical therapeutic analysis of primary nephrotic syndrome in elderly treated by combination treatment of Tripterygium wilfordii and medium dosage prednisone. Zhong Hua Lin Chuang Yi Xue Yan Jiu Za Zhi [Chinese Magazine of Clinical Medicinal Professional Research] 2003;9(12):11475-6.
9. Zhang F. Comparison of effects of Tripterygium glycosides plus prednisone with prednisone alone on primary nephrotic syndrome. Zhong Wai Jian Kang Wen Zhai - Yi Yao Yue Kan [World Health Digest - Medical Monthly] 2007;4(8):96-8.
10. Zhao DG, Zhao X. Synergism of Tripterygium glycosides and prednisone for the complementary treatment of nephrotic syndrome. Changchun Zhongyiyao Daxue Xuebao [Journal of Changchun University of Traditional Chinese Medicine] 1997;13(4):20-1.
11. Zhao L. Comparative observation of effects of Tripterygium glycosides versus cyclophosphamide for the treatment of refractory nephrotic syndrome. Hebei Yi Yao [Hebei Medical Journal] 2009;31(16):2160-1.
12. Chang H, Li HP. Clinical analysis of 52 patients with nephrotic syndrome treated by Tripterygium glycosides and Fu Fang Dan Shen (active ingredients were Radix Salviae Miltiorrhizae and Lignum Dallbergiae Odoriferae). Zhong Guo Lin Chuang Yi Yao Yan Jiu Za Zhi [Chinese Journal of Clinical Medicine Research] 2005;11(4):14919-20.
13. Du XY. Clinical observation of effects of combined treatment for 50 patients with nephrotic syndrome. Zhong Guo Xian Dai Yao Wu Ying Yong [Chinese Journal of Modern Drug Application] 2008;2(11):98-9.
14. Han SL, Li GX, Zhou LH, Huang S, Ling YS. Clinical therapeutic observation of prednisone plus Tripterygium glycosides in the treatment of nephrotic syndrome (type I). Zhongguo Zhongxiyi Jiehe Shenbing Zazhi [ChineseJournalof Integrated Traditional and Western Nephrology] 2001;2(2):115-6.
15. Hu GH, Yi ZW, Wang JH, Yao JC. Effect of triptergium wilfordii polyglycosidium on content of Th1 and Th2 in child recurrent nephrotic syndrome. Zhongguo Zhongyao Zazhi [China Journal of Chinese Materia Medica] 2008; Vol. 33, issue 4:441-3. [CN-00716138]
16. Huang GH. Therapeutic effect analysis of Tripterygium wilfordii on the treatment of chronic nephrosis. Shiyong Linchuang Yixue [Practical Clinical Medicine] 2003;4(2):48.
17. Li Z, Meng H, Hong J. Clinical observation of 37 patients of nephrotic syndrome treated by combined treatment of Tripterygium wilfordii, Radix Astragali Mongolici, and quadruple chemotherapy. Zhongguo Quanke Yixue [Chinese General Practice] 2003;6(3):248.
18. Lin X, Yang FF, You YW, Chen LX, Wang J, Li SL. Clinical efficacy of double dosage of Tripterygium wilfordii with intermittent maintenance therapy in treatment of primary nephrotic syndrome. Youjiang Minzu Yixueyuan Xuebao [Journal of Youjiang Medical College for Nationalities] 2005;27(3):282-4.
19. Liu AM, Wang YP, Dai YW, Yang C, Tang HY. Clinical observation of the re-treatment after relapse in children with primary nephrotic syndrome. Zhejiang Zhongyi Zazhi [Zhejiang Journal of Traditional Chinese Medicine] 2003;38(3):334.
20. Liu CM, Liu Y, Xu K. Clinical therapeutic observation of Tripterygium glycosides for the treatment of nephrotic syndrome. Guizhou Yiyao [Guizhou Medical Journal] 2003;27(5):442-4.
21. Liu ZH, Yuan F, Wang YF. Tripterygium wilfordii combined with prednisone in the treatment of refractory primary nephrotic syndrome. Zhong Guo Yi Xue Chuang Xin [Medical Innovation of China] 2010;7(3):1-2.
22. Lu XT. Combined Tripterygium wilfordii and prednisone for the treatment of nephrotic syndrome. Xiandai Zhongxiyijiehe Zazhi [Modern Journal of Integrated Traditional Chinese and Western Medicine] 2003;12(10):1058.
23. Ma P. Effect of Tripterygium wilfordii combined with small-dosage prednisone on nephrosis syndrome. Linchuang Huicui [Clinical Focus] 1991;6(5):210-1.
24. Mo XX. Effect of Tripterygium wilfordii combined with leflunomide on refractory nephrosis syndrome. Zhongguo Shequ Yishi [Chinese Community Doctors] 2009;11(10):54-5.
25. Pang W, Fu HF, Tang DS. Clinical observation of integrated traditional Chinese and western medicine in treatment of nephrotic syndrome. Guangzhou Yixueyuan Xuebao [Academic Journal of Guangzhou Medical College] 1999;27(3):43-5.
26. Song B. Comparison between the therapeutic effects of cyclophosphamide and Tripterygium wilfordii hook on children refractory nephrotic syndrome. Zhong Guo Shi Yong Yi Yao [China Practical Medicine] 2008;3(14):7-8.
27. Sun XH, Li HJ, Han W, Li BH. Observation on the therapeutic effect of the prednisone, Tripterygium wilfordii, ligustrazin in old age primary nephrotic syndrome. Xin Jiang Yi Ke Da Xue Xue Bao [Journal of Xinjiang Medical University] 2008;31(6):676-8.
28. Tang XL, Hong SJ, Tang LL. Clinical therapeutic observation of combined Tripterygium wilfordii and ticlopidine in treatment of refractory nephrotic syndrome. Zhongguo Zhongxiyi Jiehe Shenbing Zazhi [ChineseJournalof Integrated Traditional and Western Nephrology] 2004;5(1):27.
29. Wang KL, Wang DM. Effects of combination of prednisone and Tripterygium wilfordii in 30 patients with primary nephrotic syndrome. Da Li Yi Xue Yuan Xue Bao [Journal of Dali Medical College] 1996;5(4):36-7.
30. Wang HW, Chen JH. Comparison of effects of Tripterygium wilfordii and prednisone in treatment of nephrotic syndrome in elderly. Youjiang Minzu Yixueyuan Xuebao [Journal of Youjiang Medical College for Nationalities] 2000;22(6):883-4.
31. Wang QY, Zhao XH, Zhou WY, Wang XY. Clinical study of combined Tripterygium wilfordii and Shu Xue Tong injection in treatment of refractory nephrosis in adults. Zhongguo Zhongxiyi Jiehe Shenbing Zazhi [ChineseJournalof Integrated Traditional and Western Nephrology] 2001;2(10):606-7.
32. Wang QY, Zhou WY, Zhao XH. Clinical study of combined Tripterygium wilfordii and Shu Xue Tong injection in treatment of refractory nephrosis in adults. Heilongjiang Yi Xue [Heilongjiang Medical Journal] 2001;14(3):212.
33. Wang LN, Tang XZ, Chen PP. Clinical therapeutic observation of prednisone plus Tripterygium wilfordii for the treatment of nephrotic syndrome. Zhongguo Zhongxiyi Jiehe Shenbing Zazhi [ChineseJournalof Integrated Traditional and Western Nephrology] 2002;3(7):418-9.
34. Wang DY. Clinical therapeutic observation of combined Tripterygium wilfordii and lumbrokinase in the adjunctive treatment of primary nephrotic syndrome. Jiangxi Yiyao [Jiangxi Medical Journal] 2005;40(Suppl):694-6.
35. Wang KM, Lai XH, Xu RF. Tripterygium wilfordii for the treatment of refractory primary nephrotic syndrome. Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional and Western Medicine] 2005;15(6):341-2.
36. Wang YL. Clinical observation of integrated traditional Chinese and western medicine in treatment of nephrotic syndrome. Zhongyuan Yikan [Central Plains Medical Journal] 2006;33(10):60-1.
37. Wen JF, Cao JX. Observation of effects of Tripterygium wilfordii and heparin on nephrotic syndrome. Zhongguo Xiandai Yixue Zazhi [China Journal of Modern Medicine] 1996;6(2):42.
38. Xiao HQ, Ding GH, Zhang JE, Zhang QH, Li T, Luo CX. Comparison between the therapeutic effects of Tripterygium wilfordii and cyclophosphamide on primary nephrotic syndrome. Linchuang Huicui [Clinical Focus] 2003;18(18):1039-40.
39. Xiao HQ, Zhang JE, Ye CY. Effects of Tripterygium wilfordii on primary nephrotic syndrome. Lin Chuang Shen Zang Bing Za Zhi [Journal of Clinical Nephrology] 2001;1(3):131-3.
40. Xiao YC. Clinical therapeutic observation of 56 patients with primary nephrotic syndrome treated by Tripterygium wilfordii. Shi Yong Quan Ke Yi Xue [Applied Journal of General Practice] 2007;5(4):312-3.
41. Xu ZH, Hou CA, Chen Y, Xue QZ. Clinical observation of integrated traditional Chinese and western medicine in treatment of nephrotic syndrome. Shi Yong Zhong Xi Yi Jie He Za Zhi [The Practical Journal of Integrating Chinese with Modern Medicine] 1998;11(1):62.
42. Xu YZ, Huang ZQ, Tang R. Effect of Tripterygium wilfordii together with prednisone in treatment of elderly primary nephrotic syndrome. Zhongguo Jiceng Yiyao [Chinese Journal of Primary Medicine and Pharmacy] 2009;16(5):781-2.
43. Yang XH, Yu RF. Therapeutic observation of 40 patients with primary nephrotic syndrome and infection. Shiyong Yixue Zazhi [Journal of Practical Medicine] 1995;11(11):725-6.
44. Yang LR. Combination of Tripterygium wilfordii and levamisole for the treatment of 41 patients with nephrotic syndrome. He Nan Yi Yao Xin Xi [Henan Medical Information] 2002;10(14):58-9.
45. Yang J, Fan LH. Therapeutic observation of Tripterygium wilfordii and prednisone in the treatment of primary nephrotic syndrome. Zhong Guo Shi Yong Yi Yao [China Practical Medical] 2010;5(16):161-2.
46. Ye YJ. Therapeutic observation of effect of combined leflunomide and tripterygium on refractory nephrotic syndrome. Jilin Yixue [Jilin Medical Journal] 2010;31(6):773.
47. Zhai XS, Zhou TG, Zou Y, Chen T. Clinical therapeutic analysis of 32 patients with nephrotic syndrome treated by Tripterygium wilfordii and prednisone. Xian Dai Yi Yao Wei Sheng [Modern Medicine Health] 2004;20(21):2246-7.
48. Zhang CF, Wang Z, Wang ML, Hua MN. Therapeutic analysis of 70 patients with nephrotic syndrome. Zhong Guo Shi Yong Yi Yao [China Practical Medical] 2007;2(36):137-8.
49. Zhang X, He XM, Du WB, Zhao CL. Effect of Tripterygium wilfordii combined with moiety prednisone on treatment of the aged nephrosis syndrome. Zhongguo Jiceng Yiyao [Chinese Journal of Primary Medicine and Pharmacy] 2010;17(5):623-5.
50. Zheng DH, Su P, Fang JY, Wei HM. Clinical therapeutic observation of 26 patients with nephrotic syndrome treated by Tripterygium wilfordii and urokinase. Huazhong Yixue Zazhi [Central China Medical Journal] 1987;11(2):77-8.
51. Zhong ZH, Lu JJ, Cai CD. Clinical analysis of 30 patients with refractory nephrotic syndrome treated by prednisone and Tripterygium wilfordii. Zhong Guo Zong He Lin Chuang [Clinical Medicine of China] 2002;18(5):435-6.
52. Zhou YC. Tripterygium wilfordii in combination with small-dosage prednisone for the treatment of nephrotic syndrome. Hebei Yixue [Hebei Medicine] 1999;5(4):14-6.
53. Zhou YZ. Clinical therapeutic observation of integrated traditional Chinese and western medicine in treatment of primary nephrotic syndrome. Hebei Zhongyi [Hebei Journal of Traditional Chinese Medicine] 2000;22(8):620-1.
54. Bao J, Dai SM. A Chinese herb Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: mechanism, efficacy, and safety. Rheumatology International 2011;31(9):1123-9. [MEDLINE: 21365177]
55. Bonilla-Felix M, Parra C, Dajani T, Ferris M, Swinford RD, Portman RJ, et al. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney International 1999;55(5):1885-90. [MEDLINE: 10231451]
56. Chen SY. Effect of Tripterygium wilfordii on the remission of proteinuria in patients with nephrotic syndrome. Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional and Western Medicine] 1985;5(3):164-6, 132. [MEDLINE: 3157498]
57. Chen YZ, Gao Q, Zhao XZ, Chen XM, Zhang F, Chen J, et al. Meta-analysis of Tripterygium wilfordii hook F in the immunosuppressive treatment of IgA nephropathy. Internal Medicine 2010;49(19):2049-55. [MEDLINE: 20930429]
58. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003;362(9384):629-39. [MEDLINE: 12944064]
59. Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2009;151(4):229-40, W49-51. [MEDLINE: 19687490]
60. Gulati S, Sharma AP, Sharma RK, Gupta A. Changing trends of histopathology in childhood nephrotic syndrome. American Journal of Kidney Diseases 1999;34(4):646-50. [MEDLINE: 10516344]
61. Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: A comparison of renal biopsy findings from 1976-1979 and 1995-1997. American Journal of Kidney Diseases 1997;30(5):621-31. [MEDLINE: 9370176]
62. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
63. Hong Y, Zhou W, Li K, Sacks SH. Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cells. Kidney International 2002;62(4):1291-300. [MEDLINE: 12234299]
64. Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BMJ 2008;336(7654):1185-9. [MEDLINE: 18497417]
65. Anonymous. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney International 1978;13(2):159-65. [MEDLINE: 713276]
66. Jiang X. Clinical observations on the use of the Chinese herb Tripterygium wilfordii Hook for the treatment of nephrotic syndrome. Pediatric Nephrology 1994;8(3):343-4. [MEDLINE: 7917863]
67. KDIGO. Idiopathic membranous nephropathy. Kidney International - Supplement 2012;2:186-97.
68. Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial prevalence of glomerular lesions in nephrotic adults. American Journal of Kidney Diseases 1996;27(5):647-51. [MEDLINE: 8629623]
69. Kupchan SM, Court WA, Dailey RG, Jr, Gilmore CJ, Bryan RF. Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. Journal of the American Chemical Society 1972;94(20):7194-5. [MEDLINE: 5072337]
70. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. [MEDLINE: 20332511]
71. Pildal J, Hrobjartsson A, Jorgensen KJ, Hilden J, Altman DG, Gotzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. International Journal of Epidemiology 2007;36(4):847-57. [MEDLINE: 17517809]
72. Sharma M, Li JZ, Sharma R, Artero M, Ge X, McCarthy ET, et al. Inhibitory effect of Tripterygium wilfordii multiglycoside on increased glomerular albumin permeability in vitro. Nephrology Dialysis Transplantation 1997;12(10):2064-8. [MEDLINE: 9351066]
73. Srivastava T, Simon SD, Alon US. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatric Nephrology 1999;13(1):13-8. [MEDLINE: 10100283]
74. Tao XL, Dong Y, Zhang NZ. A double-blind study of T2 (tablets of polyglycosides of Tripterygium wilfordii hook) in the treatment of rheumatoid arthritis. Zhonghua Nei Ke Za Zhi [Chinese Journal of Internal Medicine] 1987;26(7):399-402, 44-5. [MEDLINE: 3322706]
75. Tao XL, Sun Y, Dong Y, Xiao YL, Hu DW, Shi YP, et al. A prospective, controlled, double-blind, cross-over study of Tripterygium wilfordii hook F in treatment of rheumatoid arthritis. Chinese Medical Journal (English) 1989;102(5):327-32. [MEDLINE: 2509153]
76. Tao X, Cai JJ, Lipsky PE. The identity of immunosuppressive components of the ethyl acetate extract and chloroform methanol extract (T2) of Tripterygium wilfordii Hook. F. Journal of Pharmacology & Experimental Therapeutics 1995;272(3):1305-12. [MEDLINE: 7891348]
77. Tao X, Schulze-Koops H, Ma L, Cai J, Mao Y, Lipsky PE. Effects of Tripterygium wilfordii hook F extracts on induction of cyclooxygenase 2 activity and prostaglandin E2 production. Arthritis & Rheumatism 1998;41(1):130-8. [MEDLINE: 9433878]
78. Tao X, Cush JJ, Garret M, Lipsky PE. A phase I study of ethyl acetate extract of the Chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid arthritis. Journal of Rheumatology 2001;28(10):2160-7. [MEDLINE: 11669150]
79. Tao X, Younger J, Fan FZ, Wang B, Lipsky PE. Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis & Rheumatism 2002;46(7):1735-43. [MEDLINE: 12124856]
80. Wan Y, Gu L, Suzuki K, Karasawa T, Fujioka Y, Han GD, et al. Multi-glycoside of Tripterygium wilfordii Hook f. ameliorates proteinuria and acute mesangial injury induced by anti-Thy1.1 monoclonal antibody. Nephron. Experimental Nephrology 2005;99(4):e121-9. [MEDLINE: 15722645]
81. Wan Y, Sun W, Zhang H, Yan Q, Chen P, Dou C, et al. Multi-glycoside of Tripterygium wilfordii Hook F. ameliorates prolonged mesangial lesions in experimental progressive glomerulonephritis. Nephron. Experimental Nephrology 2010;114(1):e7-14. [MEDLINE: 19816047]
82. Wen ZH, Xu WH, Lai SL. Causal relationship of adverse reactions with tripterygium in 38 patients. Zhongyao Xinyao Yu Linchuang Yaoli [Traditional Chinese Drug Research & Clinical Pharmacology] 1999;10(1):50-3.
83. Xu G, Tu W, Jiang D, Xu C. Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta-analysis. Nephron. Clinical Practice 2009;111(4):c223-8. [MEDLINE: 19287181]
84. Zheng CX, Chen ZH, Zeng CH, Qin WS, Li LS, Liu ZH. Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney International 2008;74(5):596-612. [MEDLINE: 18509322]
85. Chen YZ, Zhao XZ, Yuan Q. Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD008568]